Inhibrx Biosciences INBX
NASDAQ INBX
$90.61 -1.13 (-1.23%)
At close: Nov 10, 2026 · 4:00 PM EST

Inhibrx Biosciences (INBX) EBIT (2023 - 2026)

Updated

Inhibrx Biosciences (INBX) recorded EBIT of -$32.15 million in Q2 2026, compared with -$27.39 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) EBIT (2023 - 2026) Analysis & Trends

On a TTM basis, Inhibrx Biosciences' EBIT came in at -$124.27 million as of Jun 30, 2026; for FY2025, it came in at -$135.03 million.

  • Across earlier years, EBIT came in at -$331.45 million in FY2024 and -$219.22 million in FY2023.
  • Quarterly EBIT has ranged from -$160.9 million in Q2 2024 to -$27.39 million in Q2 2025 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 12.79 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 6.18 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 6.27 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 5.59 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 4.75 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 3.16 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 3.71 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 3.46 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 5.47 Bn
10 Inhibrx Biosciences 1.45 Bn 882.42 Mn - -32.15 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -32.15 Mn
Dec 31, 2025 -30.92 Mn
Sep 30, 2025 -33.81 Mn
Jun 30, 2025 -27.39 Mn
Mar 31, 2025 -42.90 Mn
Dec 31, 2024 -49.93 Mn
Sep 30, 2024 -46.80 Mn
Jun 30, 2024 -160.90 Mn
Mar 31, 2024 -73.83 Mn
Dec 31, 2023 -88.29 Mn
Sep 30, 2023 -45.83 Mn
Jun 30, 2023 -41.34 Mn
API Access

Inhibrx Biosciences EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit&ticker=INBX&period=max&api_key=YOUR_API_KEY